Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Startups channel feed
Venrock takes the wrap off its first microbiome startup, armed with $50M, a CEO from 23andMe and two founders from Stanford
5 years ago
Financing
The latest Jennifer Doudna startup launches with a Biogen partnership and eyes on big targets few CRISPR companies have chased
5 years ago
People
The Endpoints 11: Here are some of the most promising startups in biotech. And Covid-19 isn't going to stop them
5 years ago
Special
A pharma exec gets $100M to chase a cancer-fighting idea uncovered in a 2017 Novartis study
5 years ago
Financing
With a $4M federal grant, Lumen jumps into the Covid-19 treatment race
5 years ago
Coronavirus
Flagship's next big technological bet? The cloud
5 years ago
Financing
With $29M in Series A, Boehringer-backed Libra looks to tackle neurodegeneration through cellular cleaning
5 years ago
Financing
Immetas Therapeutics nabs $11M Series A to narrow their bispecific work targeting inflammation in age-related diseases
5 years ago
Financing
Discovery
Can a magnetic cell therapy replace corneal transplantation? As eight-year journey leads to the clinic, two brothers unveil bold vision
5 years ago
Cell/Gene Tx
Lava breaks prolonged silence with an $83M Series C and two I/O programs set for the clinic
5 years ago
R&D
Versant teams up with Stanford gene editing experts on a $45M next-gen play — marrying CRISPR and AAV to fix sickle cell
5 years ago
Financing
Cell/Gene Tx
Arie Belldegrun and David Chang godfather the $110M launch of a new cell therapy player. And this one is also thinking big
5 years ago
R&D
Exclusive: Ginkgo teams with unknown upstart in hunt for Covid-19 antibody
5 years ago
Coronavirus
FL56+FL57= infinite possibilities? Flagship's hybrid startup takes machine learning in drug discovery to the next level — and Covid-19 offers a quick test
5 years ago
AI
New targeted therapy approaches win Rain Therapeutics $63M — designed to beat a quick path to approval
5 years ago
Financing
A pair of Bay Area biotech upstarts with deep pockets and a shared interest in curative cancer drugs join R&D forces
5 years ago
R&D
Driving to the $278M mark on raises, a legendary R&D expert sets his sights on another pivotal goal line
5 years ago
People
Financing
'We want to be everywhere.' Mission Bio raises $70M behind resistance-hunting sequencing platform
5 years ago
Financing
Perceptive births its first in-house startup — and it's a China play
5 years ago
Deals
China
RA Capital-backed Aerovate launches with $72.6M to treat PAH with a repurposed cancer med
5 years ago
Versant funds TCR therapy biotech T-knife's $78M+ Series A to boost humanized T cell mice platform
5 years ago
Financing
Less than 3 months after launch, the AveXis crew’s Taysha raises $95M Series B. Is an IPO next?
5 years ago
Financing
Versant debuts Ridgeline's startup #4, armed with $30M and alternative TCR cell therapies for solid tumors
5 years ago
Financing
IgGenix emerges from stealth with $10 million Series A hoping to re-engineer allergic cascade
5 years ago
Financing
First page
Previous page
51
52
53
54
55
56
57
Next page
Last page